Cetuximab plus FOLFOX 6 as first line therapy for metastatic colorectal cancer

被引：0
|
作者：
Scott, J
Dakhil, S
Cosgriff, T
Pink, C
Butler, B
Boccia, RV
机构：
[1] Canc Ctr Kansas, Wichita, KS USA
[2] Int Oncol Network, Wichita, KS USA
[3] Hematol & Oncol Specialists LLC, New Orleans, LA USA
[4] Canc Ctr Colorado Springs, Colorado Springs, CO USA
[5] Int Oncol Network Clin Res, Baltimore, MD USA
[6] Ctr Canc & Blood Disorders, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：297S / 297S
页数：1
相关论文
共 50 条
  • [21] Results of the use of oxaliplatin and capecitabine plus cetuximab as first-line therapy in the treatment of patients with metastatic colorectal cancer:: First analyses
    Barroso, S.
    Sanches, E.
    Marques, Ferreira J.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sottomayor, C.
    Espirito, Santo J.
    San-bento, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 74 - 75
  • [22] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    Ocvirk, J.
    Boc, M.
    Rebersek, M.
    Mesti, T.
    Ebert, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
    Moe, M.
    Micallef, R. A.
    Pwint, T.
    Maughan, T.
    Mort, D.
    Wagstaff, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Clinical and Economic Evaluation of First-line Therapy with FOLFIRI or Modified FOLFOX6 for Metastatic Colorectal Cancer
    Ajima, Hidetomo
    Ogata, Hiroyasu
    Fujita, Ken-ichi
    Miwa, Keisuke
    Sunakawa, Yu
    Mizuno, Keiko
    Ishida, Hiroo
    Yamashita, Keishi
    Nakayama, Hirofumi
    Kawara, Kaori
    Takahashi, Harumi
    Sasaki, Yasutsuna
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (07) : 634 - 638
  • [25] Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
    Argiles, Guillem
    Saunders, Mark P.
    Rivera, Fernando
    Sobrero, Alberto
    Benson, Al, III
    Guillen Ponce, Carmen
    Cascinu, Stefano
    Van Cutsem, Eric
    Macpherson, Iain R.
    Strumberg, Dirk
    Koehne, Claus-Henning
    Zalcberg, John
    Wagner, Andrea
    Garosi, Vittorio Luigi
    Grunert, Julia
    Tabernero, Josep
    Ciardiello, Fortunato
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (08) : 942 - 949
  • [26] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [27] FOLFOX-6 PLUS IMATINIB, BEVACIZUMAB AND CETUXIMAB IN ADVANCED UNTREATED COLORECTAL CANCER
    Andretta, V
    Bennicelli, E.
    Pessino, A.
    Caprioni, F.
    Decian, F.
    Di Benedetto, M.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 113 - 113
  • [28] A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Ciuleanu, T. E.
    Kurteva, G.
    Ocvirk, J.
    Beslija, S.
    Koza, I.
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Scheithauer, W.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Results of a phase II trial of cetuximab plus XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer
    Cartwright, T. H.
    Kuefler, P.
    Cohn, A.
    Hyman, W.
    Yoffe, M.
    Boehm, K. A.
    Ilegbodu, D.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Intensified First Line Therapy of the metastatic colorectal Cancer with FOLFOXIRI plus Bevacizumab
    Ruessel, J.
    ONKOLOGE, 2015, 21 (04): : 334 - 335
12345